Evidence map›Paper›PMID 38801501›Full record

ArticleAIDS and behavior2024

Evaluating Dual Process Decision-Making Along the PrEP Consumer Journey: New Insights for Supporting PrEP Use.

Benjamin Lane, Nadia Nguyen, Harrison Fillmore, Caroline Carnevale, Magdalena E Sobieszczyk, Jason Zucker, Kathrine Meyers

Abstract read
In one paragraph

Article in AIDS and behavior, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Benjamin LaneAaron Diamond AIDS Research Center, Columbia University Irving Medical Center, New York, NY, USA.
Nadia NguyenAaron Diamond AIDS Research Center, Columbia University Irving Medical Center, New York, NY, USA.
Harrison FillmoreDivision of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, 701 West 168th Street, 11th floor, New York, NY, 10032, USA.
Caroline CarnevaleNew York Presbyterian Hospital, New York, NY, US.
Magdalena E SobieszczykDivision of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, 701 West 168th Street, 11th floor, New York, NY, 10032, USA.
Jason ZuckerDivision of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, 701 West 168th Street, 11th floor, New York, NY, 10032, USA. Jz2700@cumc.columbia.edu.ORCID http://orcid.org/0000-0001-6987-6412
Kathrine MeyersAaron Diamond AIDS Research Center, Columbia University Irving Medical Center, New York, NY, USA. kam2157@cumc.columbia.edu.ORCID http://orcid.org/0000-0002-8573-1958

Funding

Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials UnitUM1AI069470 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAGDALENA ELZBIETA SOBIESZCZYK · 2012 to 2026
$44.8M
Synthesizing Best Practice to Accelerate Access to Emerging HIV Prevention ModalitiesR01MH123262 · NIMH · HUNTER COLLEGE · PI GOLUB, SARIT A, MEYERS, KATHRINE · 2020 to 2024
$4.2M
Harnessing Bioinformatics for HIV Prevention: Understanding Persistence in Comprehensive HIV Prevention ServicesK23AI150378 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ZUCKER, JASON · 2020 to 2024
$960k
Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases K23AI150378Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases UM1AI069470NIAID NIH HHS K23 AI150378NIAID NIH HHS UM1 AI069470NIMH NIH HHS R01 MH123262NIMH NIH HHS R01MH123262
6 · The paper itself

Abstract

With the rise of new and emerging Pre-Exposure Prophylaxis (PrEP) modalities, greater attention is needed to better understand how people who could benefit from PrEP make decisions to initiate, stop, pause, or switch PrEP regimens. In this study we borrow from the field of consumer research to create a consumer-derived PrEP Consumer Journey Model that describes key decision-making touchpoints a PrEP consumer moves through within and outside of a clinical context. Using in-depth interviews (n = 29) with gay and bisexual men who have sex with men, we evaluate which system 1 (emotional) and system 2 (cognitive) attributes are used for decision-making at different touchpoints along the PrEP Consumer Journey. Our results suggest system 1 attributes, such as feeling protected, reducing anxiety, enhancing pleasure, social norms, and taking ownership over health were more salient when consumers moved from pre-contemplation to information gathering, as well as evaluating post-uptake experience. System 2 attributes, including cost, side effects, dosing schedule, and sexual frequency, were present throughout the PrEP Consumer Journey, but particularly influential in the information gathering stage and when pausing, switching, or opting out of PrEP. We contend the PrEP Consumer Journey, and our findings related to decision-making, can help orient medical providers to anticipated patient concerns around PrEP use and ultimately provide more supportive and engaging PrEP counseling and services.

Indexed as

Decision MakingHIV InfectionsHomosexuality, MalePre-Exposure ProphylaxisAdultAnti-HIV AgentsHumansInterviews as TopicMaleMiddle AgedQualitative ResearchSexual and Gender MinoritiesAnti-HIV Agents

Identifiers

PMID38801501
PMCPMC11390328

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.